Neurology News

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. Food and Drug Administration review of the Company’s Premarket Approval Panel Track Supplement seeking to expand the labeled indication for the RNS® System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE). NeuroPace has received a communication from FD...

BOSTON--(BUSINESS WIRE)--REEV launches its pivotal clinical study of the DREEVEN robotic knee brace in post-stroke mobility in clinical and home settings....

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--BrainChip Holdings Ltd. (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), a global leader in ultra-low power, fully digital, event-based neuromorphic AI, today announced that its AKD1500 chip based on the Akida™ neuromorphic processor is now available in the compact M.2 form factor, enabling fanless, plug-and-play edge AI for industrial and commercial designs.The new AKD1500 M.2 module is positioned as a low-cost, ultra-low-power edge AI accelerator available for plug-...

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that Highmark Inc. has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy, for eligible members when clinically appropriate and medically necessary, in accordance with members’ health plan benefits and applicable coverage guidelines. The policy went into effect on July 27, 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the c...

BOSTON--(BUSINESS WIRE)--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appointment of Rohan Palekar to its Board of Directors. Most recently, Mr. Palekar served as founding Chief Executive Officer at 89bio where he led multiple programs from preclinical studies through Phase 3 development in liver and cardiometabolic diseases. 89bio was acquired by Roche in 2025 for up to $3.5 billion. In c...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today, to discuss these financial results and expectations, and provide an update on the company. The webcast ma...

STAMFORD, Conn.--(BUSINESS WIRE)--Neuvotion, Inc. is an early-stage medical device company developing an AI-guided neuromodulation platform to accelerate recovery after neurological events such as stroke and spinal cord injury. Its Brain-Body Interface (BBI) portfolio integrates wearable high-resolution muscle stimulation, spinal neuromodulation, and minimally invasive brain-computer interface (BCI) technologies to restore movement and sensation. By combining AI, intention-driven neurostimulati...

MANHASSET, N.Y.--(BUSINESS WIRE)--Northwell Health’s Feinstein Institutes for Medical Research has announced the groundbreaking release of the world’s first comprehensive human vagus nerve anatomical map, an achievement set to change our understanding of the autonomic nervous system and accelerate the development of bioelectronic medicine and neuromodulation therapies. The first dataset release, meticulously collected over three years from 30 human donors encompassing 60 vagus nerves, is now wi...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior r...

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine will report Q2 2026 financial results Thur., Aug. 6, 2026. Management will host a corresponding conference call at 1:30 PM PT/4:30 PM ET....